Formulation Development
Emergent BioSolutions Announces Initiation of Pivotal Phase 3 Study Evaluating the Safety & Immunogenicity of Its Single-Dose Chikungunya Vaccine Candidate
Emergent BioSolutions Inc. recently announced the first participant dosed in its pivotal Phase 3 study evaluating the safety and immunogenicity of the company’s investigational chikungunya…
CEL-SCI’s Multikine Immunotherapy Produces Significant Survival Benefit in the Group Receiving Surgery Plus Radiotherapy in a Landmark Head & Neck Cancer Phase 3 Study
CEL-SCI Corporation recently announced results from its 9.5 year pivotal Phase 3 study for its immunotherapy Multikine (Leukocyte Interleukin, Injection)* in the treatment of advanced…
Evonik Launches Next-Generation LIPEX Extruder for Fast & Effective Liposomal Drug Manufacturing
Evonik has launched a new version of its industry renowned drug manufacturing equipment LIPEX liposome extruders. LIPEX Flow, which is available worldwide from November 2021,…
Ascendia Once Again Ranked on Inc. 5000 List of America’s Fastest-Growing Private Companies
Inc. magazine revealed that Ascendia Pharmaceuticals rose 3,239 positions on its annual Inc. 5000 list, the most prestigious ranking of the nation’s fastest-growing private companies…..
Viridian Therapeutics Submits IND Application for an IGF-1R Antibody for the Treatment of Thyroid Eye Disease
Viridian Therapeutics, Inc. recently announced the submission of an investigational new drug (IND) application to the United States Food and Drug Administration (FDA). The company…
Omega Therapeutics Announces Strategic Research Collaboration With Stanford University School of Medicine
Omega Therapeutics, Inc. recently announced a strategic research collaboration with researchers at the Stanford University School of Medicine to explore the therapeutic potential of Omega Epigenomic…
TFF Pharmaceuticals & Augmenta Bioworks Publish Positive In Vivo Data Showing Dry Powder Formulation of COVID-19 Antibody Neutralizes SARS-CoV-2 Infection & Reduces Viral Load
TFF Pharmaceuticals, Inc. and Augmenta Bioworks recently announced the publication of a research paper highlighting positive preclinical study results of AUG-3387, a monoclonal antibody (mAb)…
Progenity Announces Several Patents Granted by USPTO, Strengthening the Company’s Intellectual Property Position in Ingestible Therapeutics Technologies
Progenity, Inc. recently announced the United States Patent and Trademark Office (USPTO) has issued four patents related to its ingestible technologies for delivery of therapeutics…
LEXEO Therapeutics & FUJIFILM Diosynth Biotechnologies Announce Collaboration to Support Development & Manufacturing of Gene Therapies for Genetic Diseases
LEXEO Therapeutics and FUJIFILM Diosynth Biotechnologies recently announced a strategic collaboration to support the development and manufacturing of LEXEO’s AAV-mediated gene therapies. FUJIFILM Diosynth Biotechnologies…
Veru Enrolls First Patient in International Phase 3 ARTEST Clinical Trial of Enobosarm in Metastatic Breast Cancer
Veru Inc. recently announced it has enrolled the first patient in its Phase 3 ARTEST registration trial of enobosarm, an oral selective androgen receptor (AR)…
PCI Pharma Services Announces the Acquisition of LSNE to Add End-to-End Global Sterile Fill-Finish & Lyophilization Manufacturing Capabilities
PCI Pharma Services (PCI) recently announced it has signed a definitive agreement to acquire Lyophilization Services of New England, Inc. (LSNE), a premier contract development and manufacturing organization (CDMO)….
Pace Life Sciences Acquires Velesco Pharmaceutical Services, Expanding Capabilities in Drug Development Services
Pace Analytical Life Sciences, LLC, a subsidiary of Pace Analytical Services, LLC, a full-service contract development and manufacturing organization (CDMO), recently announced that it has acquired Velesco….
Centogene & Twist Bioscience to Develop Advanced Sequencing Tools to Make Genetic Testing Rapidly Accessible for More Patients With Rare Diseases
Centogene N.V. and Twist Bioscience Corporation recently announced they have signed a contract to collaborate on the development and commercialization of custom assay kits for rare diseases…..
Acer Therapeutics & Relief Therapeutics Announce FDA Acceptance for Filing of NDA
Acer Therapeutics Inc. and its collaboration partner, Relief Therapeutics Holding SA recently announced the US FDA has accepted for filing the New Drug Application (NDA) for ACER-001 (sodium phenylbutyrate) for the….
Timber Pharmaceuticals Reports Positive Top-Line Results from Phase 2b CONTROL Study Evaluating TMB-001 in Moderate-to-Severe Congenital Ichthyosis
Timber Pharmaceuticals, Inc. recently announced positive top-line data from its Phase 2b CONTROL study evaluating TMB-001, an investigational topical isotretinoin formulated using Timber's patented IPEG…
Supernus Pharmaceuticals to Acquire Adamas Pharmaceuticals, Strengthening its CNS Product Portfolio
Supernus Pharmaceuticals, Inc. and Adamas Pharmaceuticals, Inc. recently announced a definitive agreement for Supernus to acquire Adamas through a tender offer for $8.10 per share…
Pacira BioSciences to Acquire Flexion Therapeutics Further Expanding Leadership Position in Non-Opioid Pain Management
Pacira BioSciences, Inc. and Flexion Therapeutics, Inc. recently announced a definitive agreement pursuant to which Pacira will acquire Flexion for $8.50 per share in cash,…
Fortress Biotech Announces Closing of Acquisition of Caelum Biosciences by AstraZeneca
Fortress Biotech, Inc. and a company it founded, Caelum Biosciences, Inc. recently announced the closing of AstraZeneca’s acquisition of Caelum, pursuant to the Development, Option…
Acumen Announces First Patient Dosed in a Phase 1 Clinical Trial of Monoclonal Antibody
Acumen Pharmaceuticals, Inc. recently announced dosing of the first patient in INTERCEPT-AD, the Phase 1 placebo-controlled, single- and multiple-dose clinical trial of ACU193, a monoclonal…
Albireo Announces Exclusive Licensing Agreement With Jadeite Medicines
Albireo Pharma, Inc. recently entered into an exclusive licensing agreement with Jadeite Medicines, Inc. for the development and commercialization of Bylvay (odevixibat) in Japan for…
